Allogeneic CAR T-cells are derived from a healthy donor’s T-cells rather than the patient’s own cells, which offers several advantages. One key benefit is that allogeneic CAR T-cells can be manufactured in large quantities and stored for off-the-shelf use. This potentially reduces the time required for treatment and can be readily available for patients. Additionally, […]

CAR T-cells are primarily used for the treatment of certain types of blood cancers, particularly leukemia and lymphoma. They have shown remarkable success in treating relapsed or refractory cases of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), among others. Ongoing research aims to explore the potential use of CAR T-cells for other types of […]

The duration of CAR T-cells’ presence in the body varies from patient to patient and depends on multiple factors. Typically, infused CAR T-cells can persist in the body for months to years after treatment. However, their persistence may decline over time. Despite this, some CAR T-cells may remain in the body as memory T-cells, providing […]

Yes, CAR T-cells can proliferate in the body. After infusion into the patient, CAR T-cells continue to multiply and expand in numbers, creating a strong and sustained immune response against the targeted cancer cells. This proliferation is essential for the CAR T-cells to effectively locate and destroy cancer cells throughout the body. However, excessive proliferation […]

CAR T-cell therapy has shown great promise in the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. In this therapy, T-cells are extracted from the patient and genetically engineered to express chimeric antigen receptors (CARs) targeting the B-cell maturation antigen (BCMA), a protein commonly found on myeloma cells. After CAR modification, […]

The duration of CAR T-cell therapy can vary from patient to patient and depends on several factors, including the type of cancer being treated and the individual’s response to the treatment. Generally, the entire process can take a few weeks to complete. This includes the time required for leukapheresis to collect T-cells, the modification of […]

No, hair loss is not a common side effect of CAR T-cell therapy. Unlike traditional chemotherapy, which often causes hair loss due to its impact on rapidly dividing cells, CAR T-cell therapy targets cancer cells differently. During CAR T-cell therapy, the patient’s own T-cells are genetically modified to express chimeric antigen receptors (CARs) that target […]